Akari Therapeutics to Present at the Jefferies Complement Symposium
April 03 2017 - 7:00AM
Akari Therapeutics (NASDAQ:AKTX), an emerging growth,
clinical-stage biopharmaceutical company, announced today that Dr.
Gur Roshwalb, Chief Executive Officer, will present at the
Jefferies Complement Symposium on April 6, 2017, in Boston,
Massachusetts. The company is scheduled to present at 2:10 PM
ET.
About Akari Therapeutics PlcAkari is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of life-transforming treatments for a range
of rare and orphan autoimmune and inflammatory diseases caused by
dysregulation of complement C5 and Leukotriene B4 (LTB4), including
paroxysmal nocturnal hemoglobinuria (“PNH”), atypical Hemolytic
Uremic Syndrome (“aHUS”), and Guillain Barré syndrome (“GBS”).
Akari’s lead product candidate, Coversin™ complement inhibitor, a
second-generation complement inhibitor, acts on complement
component-C5, preventing the release of C5a and the formation of
C5b–9 (also known as the membrane attack complex or MAC), and
independently also inhibits LTB4 activity. C5 inhibition is growing
in importance in a range of rare autoimmune diseases related to
dysregulation of the complement component of the immune system,
including PNH, aHUS, and GBS. Exploiting the power of nature, Akari
is also developing other tick derived proteins and expects to bring
additional compounds to clinical trials over the next several
years. The pipeline is focused on developing bioengineered versions
of native tick salivary proteins that act as anti-inflammatory
compounds allowing the tick to remain on its host. These compounds
include PGP sparing LTB4 inhibitors, classical and alternative
complement inhibitors, anti-histamines, and serotonin inhibitors as
examples. Akari is also developing engineered forms that allow for
potential oral absorption, as, for example, a potential orally
absorbed C5 inhibitor, and tissue specific proteins, as, for
example, Coversin™ that acts specifically at the neuromuscular
junction for diseases like myasthenia gravis
Cautionary Note Regarding Forward-Looking
StatementsCertain statements in this press release
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected in
or suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control. Such risks and
uncertainties for our company include, but are not limited to: an
inability or delay in obtaining required regulatory approvals for
Coversin and any other product candidates, which may result in
unexpected cost expenditures; risks inherent in drug development in
general; uncertainties in obtaining successful clinical results for
Coversin and any other product candidates and unexpected costs that
may result therefrom; failure to realize any value of Coversin and
any other product candidates developed and being developed in light
of inherent risks and difficulties involved in successfully
bringing product candidates to market; inability to develop new
product candidates and support existing product candidates; the
approval by the FDA and EMA and any other similar foreign
regulatory authorities of other competing or superior products
brought to market; risks resulting from unforeseen side effects;
risk that the market for Coversin may not be as large as expected;
inability to obtain, maintain and enforce patents and other
intellectual property rights or the unexpected costs associated
with such enforcement or litigation; inability to obtain and
maintain commercial manufacturing arrangements with third party
manufacturers or establish commercial scale manufacturing
capabilities; the inability to timely source adequate supply of our
active pharmaceutical ingredients from third party manufacturers on
whom the company depends; our inability to obtain additional
capital on acceptable terms, or at all; unexpected cost increases
and pricing pressures; uncertainties of cash flows and inability to
meet working capital needs; and risks and other risk factors
detailed in our public filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K filed
on March 23, 2016. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release and we
undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.
Contact:
Investor Contact:
The Trout Group
Lee Stern
lstern@troutgroup.com
646–378–2922
Media Contact:
Susan Forman / Laura Radocaj
Dian Griesel Int'l.
(212) 825-3210
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024